Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Study findings suggest the potential to repurpose a drug that is FDA-approved for treating asthma and eczema, to enhance ...

Republican vice presidential candidate JD Vance suggested in an interview with podcast host Joe Rogan that aired Thursday ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases.

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...

A recent study led by researchers at Oregon Health & Science University has uncovered a link between hearing loss and an ...

Lyell Immunopharma, Inc.'s strong financials, innovative CAR T-cell therapies, and strategic acquisitions position it for ...

Pheast Therapeutics ("Pheast"), a biotech developing novel macrophage checkpoint therapies to defy cancer, today announced the presentation of new preclinical data for PHST001, an anti-CD24 antibody ...